Skip to content
10-Q

Quarterly Report

LARIMAR THERAPEUTICS, INC. LRMR

0001193125-26-224087

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 103.88M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$44.61M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$26.54M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $177.91M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $85.41M
Stockholders Equity Q1 2026 · Mar 31, 2026 $158.03M
Stockholders Equity Q1 2026 · Dec 31, 2025 $78.09M
Stockholders Equity Q1 2026 · Mar 31, 2025 $144.27M
Stockholders Equity Q1 2026 · Dec 31, 2024 $171.81M
Current Liabilities Q1 2026 · Mar 31, 2026 $47.76M
Current Liabilities Q1 2026 · Dec 31, 2025 $64.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $50.48M
Total Liabilities Q1 2026 · Dec 31, 2025 $67.76M
Current Assets Q1 2026 · Mar 31, 2026 $204.98M
Current Assets Q1 2026 · Dec 31, 2025 $142.02M
Total Assets Q1 2026 · Mar 31, 2026 $208.51M
Total Assets Q1 2026 · Dec 31, 2025 $145.84M
Sga Expense Q1 2026 · Mar 31, 2026 $6.09M
Sga Expense Q1 2026 · Mar 31, 2025 $4.64M
Rd Expense Q1 2026 · Mar 31, 2026 $25.03M
Rd Expense Q1 2026 · Mar 31, 2025 $26.55M
Net Income Q1 2026 · Mar 31, 2026 −$29.61M
Net Income Q1 2026 · Mar 31, 2025 −$29.28M
Operating Income Q1 2026 · Mar 31, 2026 −$31.12M
Operating Income Q1 2026 · Mar 31, 2025 −$31.19M
Capex Q1 2026 · Mar 31, 2025 $49K